Abivax (ABVX) Net Income towards Common Stockholders (2022 - 2026)

Abivax's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$56.7 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 3.01% year-over-year to -$56.7 million in Q1 2026; TTM through Mar 2026 was -$386.2 million, a 93.58% decrease from a year earlier, with the FY2025 full-year figure at -$398.0 million, down 108.72% from the prior year.
• Net Income towards Common Stockholders improved to -$56.7 million in Q1 2026 per ABVX's latest filing, from -$95.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$41.8 million in Q2 2024 and bottomed at -$179.3 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$56.7 million (2026), against an average of -$76.0 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 69.33% in 2024 and slumped 195.6% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$66.1 million in 2022, then tumbled by 107.34% to -$137.1 million in 2023, then soared by 69.33% to -$42.0 million in 2024, then sank by 126.96% to -$95.4 million in 2025, then soared by 40.52% to -$56.7 million in 2026.
• Per Business Quant, the three latest ABVX Net Income towards Common Stockholders figures stand at -$56.7 million (Q1 2026), -$95.4 million (Q4 2025), and -$179.3 million (Q3 2025).